After Pfizer Inc announced Wednesday that the covid vaccine it developed with BioNTech showed 95% efficacy in phase 3 final trial, BioNTech Chief Executive Officer, Ugur Sahin, told Reuters that vaccine deliveries could start before Christmas.
“If all goes well I could imagine that we gain approval in the second half of December and start deliveries before Christmas, but really only if all goes positively.”
“US emergency use authorization (EUA) would be applied for on Friday.”
S&P 500 futures have shrugged-off the upbeat comments, as fears over the surging covid cases intensify and dent the appetite for riskier assets.
The futures tied to the S&P 500 index drop 0.10% to 3,561, as of writing.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.